Chen, Xueyan

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., Bejar, R., Berti, E., Busque, L., Chan, J. K. C., et al. (2022) · Leukemia

Acute Myeloid Leukemia ResearchHistiocytic Disorders and Treatments

Cited by 4,274

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation

CAR-T cell therapy researchAcute Lymphoblastic Leukemia research

Cited by 2,112

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 1,156

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells

Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine

CAR-T cell therapy researchImmunotherapy and Immune Responses

Cited by 1,016

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells

Hirayama, A. V., Gauthier, J., Hay, K. A., Voutsinas, J. M., Wu, Q., Gooley, T., Li, D., Cherian, S., Chen, X., Pender, B. S., et al. (2019) · Blood

CAR-T cell therapy researchLymphoma Diagnosis and Treatment

Cited by 355